| Ytd | -61.02% | |
| 1y | -76.37% |
| Open | 4.36 | Prev Close | 4.35 | Low | 4.36 | High | 4.54 | Mkt Cap | 13.56M |
| Vol | 3.25K | Avg Vol | 61.45K | EPS | -4.80 | P/E | N/A | Forward P/E | -2.33 |
| Beta | -2.83 | Short Ratio | 3.67 | Inst. Own | 7.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.52 | 200-d Avg | 10.84 | 1yr Est | 8.25 |
FEMY News
ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovat
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgi
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- Ne
-- With fertility rates at historic lows, Femasys advances access to early infertility care through
The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shi
-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlin
CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) ar
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.06) per share which beat the analyst consensu
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg
Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating
ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovat
-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven t
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility trea
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility trea
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical perman
Femasys Inc. (NASDAQ: FEMY) ("Femasys" or the "Company"), a leading biomedical innov
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving
Femasys Inc. (NASDAQ: FEMY - Get Free Report) shares traded up 0.1% during trading on Monday. The st
Response Genetics (OTCMKTS:RGDXQ - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) are
-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support f
-- Innovative single-device solution integrates proven FemVue and FemChec ® technologies to support
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announ
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”),
Laidlaw & Co. analyst Yale Jen initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.10) per share which beat the analyst consensu
-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only n
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane
https://www.nytimes.com/2025/10/16/us/politics/trump-ivf-fertility.html
SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedi
